Effect of magnesium sulfate in prevention of pancreatitis

The effect of magnesium sulfate on prevention of pancreatitis after ERCP (Endoscopic retrograde cholangiopancreatography)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180310039017N1

Enrollment

270

Registered

2018-04-01

Start date

2018-04-20

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis. Acute pancreatitis

Interventions

Intervention 1: Intervention group: 2 g IV magnesium sulfate one hour before ERCP and 2 grams six hours after ERCP. Intervention 2: Control group: 2 g of IV placebo (normal saline) one hour before ERC

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years

Exclusion criteria

Exclusion criteria: Renal failure GFR <60 Heart block Myasthenia gravis or other Neuromuscular diseases Pregnancy and lactation Bradycardia Cirrhosis kidney stones (calcium, magnesium, ammonium, phosphate)

Design outcomes

Primary

Measure	Time frame
Incidence of pancreatitis. Timepoint: After ERCP. Method of measurement: Examination by a physician and performing tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hoda Hamid

Tehran University of Medical Sciences

h-hamid@razi.tums.ac.ir+98 21 6691 1293

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026